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The role of underlying nephropathy in the progression of renal and various intercurrent events may accelerate the dete-
disease. rioration of renal function; however, the fact that the
Background. Disease-specific pathogenic mechanisms may underlying nephropathy is probably the major determi-be major determinants of the spontaneous rate of progression
nant of the spontaneous rate of progression suggests theof chronic renal failure (CRF). To clarify the role of different
existence of a disease-specific pathogenic mechanism.underlying renal diseases, we examined the rate of CRF pro-
gression in 886 patients with chronic nephropathies. A number of clinical studies designed to evaluate the
Methods. Secondary analysis of two multicenter, prospec- factors involved in the progression of CRF have shown
tive randomized trials: the Northern Italian Cooperative study that the underlying disease is one of the factors determin-(NIC) and the AIPRI study (ACE-Inhibition in Progressive
ing the natural history of CRF [1–9], but the publishedRenal Insufficiency). Univariate and multivariate analyses of
results are equivocal, mainly because most involvedvariance were used to select the covariates possibly related
to CRF progression (estimated by means of the slope of the small and very heterogeneous populations and the data
reciprocal of SCr against time), focusing on the contributory were collected retrospectively. Furthermore, they usu-
role of primary renal diseases.
ally considered only the crude cumulative renal survivalResults. The overall rate of CRF progression was relatively
of the different nephropathies (without taking into ac-low but there was a considerable difference in the slopes relat-
ing to the underlying nephropathy (particularly evident in the count concomitant risk factors), and the fact that the
patients with chronic glomerulonephritis (CGN)). The median rate of the decline in GFR was measured using different
rate of CRF progression in both studies was more rapid in methods further complicates any comparison.
patients with polycystic kidney disease (PKD) and CGN than in
With the aim of clarifying the role of the underlyingthose with other nephropathies. Multivariate analysis showed
renal disease on CRF progression, we examined thePKD as an independent predictor of the CRF progression rate
only in the NIC Study (P , 0.0015); the selected variables in changes in renal function over time in two large cohorts
both studies predicted a variation of only 15–18% in the CRF of patients with chronic renal disease of different causes
progression rate. and severity enrolled in two multicenter, prospectiveConclusion. The underlying renal disease certainly plays a
randomized trials designed to clarify the role of proteinrole in the natural history of CRF, but the variability of the
restriction [10] and the administration of an ACE inhibi-CRF progression rates related to different renal diseases and
between individuals with the same diagnosis underlines the tor [11] in delaying CRF progression.
need for caution in evaluating risk factors and predicting single
patient outcomes.
METHODS
The study was based on the secondary analysis of the
Although chronic renal failure (CRF) progresses to- individual data contained in the databases of two large-
wards end-stage renal disease (ESRD) in the majority scale clinical trials [10, 11] involving CRF patients with
of cases, the rate of the decline in glomerular filtration various renal diseases.
rate (GFR) varies in groups of patients with different
nephropathies, and also in patients with the same dis- Patients
ease. A number of physiological and metabolic changes The Northern Italian Cooperative (NIC) study [10] was
may contribute towards progressive renal destruction, a 2-year, multicenter, randomized, prospective trial de-
signed to determine the effectiveness of dietary protein
restriction (0.6 versus 1 g protein/kg ideal body weight/day)Key words: chronic renal failure, progression, underlying renal disease,
proteinuria, hypertension on the progression of renal disease in 456 patients with
CRF. The Angiotensin-Converting-Enzyme InhibitionÓ 2000 by the International Society of Nephrology
S-49
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Table 1. Baseline characteristics of the NIC and AIPRI patients by renal diagnosis
CGN HNS CIN PKD DN Other Total
NIC study
N [% of total] 117 [28.3%] 64 [15.5%] 144 [34.7%] 69 [16.7%] — 20 [4.8%] 414 [100%]
Age, years* 43 611 5467 50 611 4769 — 48613 48611
Gender, male (%) 56 66 47 55 — 55 54
SCr, mg/dL* 3.0261.22 2.7761.10 2.9261.35 3.4161.60 — 3.2961.39 3.0261.34
Hb, g/dL* 13.361.9 13.561.5 13.462.1 13.161.8 — 12.962.1 13.361.9
Systolic BP, mm Hg* 146622 158622 150623 151620 — 151617 150622
Diastolic BP, mm Hg* 94612 96611 94613 96613 — 94611 95612
Mean BP, mm Hg* 111614 117613 113615 114614 — 113612 113614
Proteinuria, g/day† 1.3 0.4 0.5 0.1 — 1.3 0.5
(25th–75th percentile) (0.5–2.3) (0.0–0.9) (0.1–1.2) (0.0–0.6) — (0.3–2.1) (0.1–1.5)
AIPRI study
N [% of total] 170 [36.0%] 99 [21.0%] 90 [19.1%] 57 [12.1%] 19 [4.0%] 37 [7.8%] 472 [100%]
Age, years 48612 6068 53613 4869 5969 53 612 52612
Gender, male (%) 73 72 62 74 84 78 72
SCr, mg/dL 2.1660.60 1.8560.38 2.1060.70 2.3160.71 2.4060.73 2.1860.66 2.1160.63
Hemoglobin, g/dL 13.661.6 14.061.5 13.861.7 13.561.5 12.961.6 13.761.6 13.761.6
Systolic BP, mm Hg* 143614 150616 143615 144617 155615 145616 145616
Diastolic BP, mm Hg* 9067 8868 89 67 9267 86 66 9067 8967
Mean BP, mm Hg* 10868 10869 10768 10969 10967 10869 10869
Proteinuria, g/day† 1.9 0.3 0.7 0.3 3.4 0.8 0.9
(24th–75th percentile) (0.7–4.0) (0.0–0.8) (0.1–2.1) (0.1–1.1) (1.9–7.1) (0.2–3.0) (0.2–2.6)
Abbreviations are: BP, blood pressure; Hb, hemoglobin; SCr, serum creatinine.
* Values expressed as mean 6 SD
† Values expressed as median
in Progressive Renal Insufficiency (AIPRI) study [11] was used for continuous non-normally distributed vari-
ables. Univariate analysis of variance was used as the firstwas a 3-year, multicenter, prospective, double-blind, ran-
domized trial designed to determine the effect of the step to select the potential covariates possibly related to
CRF progression, estimated by means of the slope ofACE inhibitor benazepril on the progression of CRF in
583 patients with various underlying renal diseases. The the reciprocal of SCr versus time, which was considered
the main response variable. The two databases werestudy designs and their inclusion and exclusion criteria
have been reported in detail elsewhere [10, 11]. In both analyzed separately (see Appendix 1 for the list of tested
covariates), and the variables with a significance of #0.1studies, the patients were stratified on the basis of renal
function: those enrolled in the NIC Study were divided were then included in the multivariate analysis based on
the general linear model of the analysis of variance forinto three groups according to their baseline serum creat-
inine (SCr): group A (SCr 1.50–2.50 mg/dL); group B (SCr two parallel groups with three (NIC) or two (AIPRI)
strata of CRF severity. The controlled-protein diet in2.51–5.00 mg/dL); group C (SCr 5.01–7.00 mg/dL); the
AIPRI population was divided into two groups according the NIC study patients, and the placebo group of the
AIPRI study, were used as standard treatments. Theto their baseline creatinine clearance (CCr) calculated
according to Cockcroft’s formula (mild CRF: CCr 46–60 proteinuria data underwent natural logarithm transfor-
mation because of their right skewed distribution (for themL/min; moderate CRF: CCr 30–45 mL/min).
The cause of the renal disease was determined in each purposes of calculation, all zero values were considered
equivalent to 0.01 g/day). The assumption of the normal-patient on the basis of their medical history and the
results of a physical examination, urinalysis, biochemical ity of the error term required by this model was tested
using the analysis of residuals. A probability value oftests, and radiological and ultrasonographic studies; most
of the patients with proteinuria also underwent renal less than 0.05 was considered statistically significant. The
statistical analyses were made using SPSS for Windows,biopsy. All of the diagnoses were confirmed by a Quality-
Control and End-point Evaluation Committee. Release 9.0.
Statistical analysis
RESULTS
The individual data were used to calculate the individ-
Baseline characteristicsual patient slopes of the reciprocal of SCr versus time,
which was subsequently used to test the effect on CRF From a total of 1039 patients (456 NIC and 583 AIPRI
patients), we selected the 886 patients (414 NIC and 472progression of the underlying renal disease and some
baseline and follow-up clinical covariates. Percentile dis- AIPRI) for whom at least three post-randomization SCr
measurements were available; their baseline characteris-tribution (with the median as central tendency statistic
and 25th and 75th percentile values as variability indices) tics and the causes of CRF are summarized in Table 1.
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Fig. 1. Frequency distribution of the slopes of the reciprocal of SCr versus time in the NIC study [10] overall and according to renal disease.
Baseline renal function was better in the AIPRI than in the interquartile range) is greater in the former than the
latter. In both studies, the patients with CGN and PKDthe NIC study (SCr 2.11 6 0.62 mg/dL versus 3.04 6 1.36
mg/dL), but median proteinuria was higher (0.9 versus showed a faster rate of CRF progression (the boxes are
below the zero reference line, which indicates no pro-0.6 g/day) and its greater interquartile range (2.4 versus
1.4 g/day) suggested a higher degree of variability. Mean gression in renal disease). Progression was fastest in the
patients with diabetic nephropathy (DN), but these wereblood pressure was lower in the AIPRI study (108 6 9
mm Hg versus 113 6 14 mm Hg). few in number and restricted to the AIPRI study.
The percentile distribution of the slopes in the two
Rate of CRF progression studies (overall and by underlying renal disease) are
shown in Table 2. The median overall slopes were 20.027Figure 1 and Figure 2 show the distribution of the
linear slopes of the reciprocal of SCr in the two groups: dL/mg/year in the NIC and 20.029 dL/mg/year in the
AIPRI study. The 75th percentile values were, respec-in both studies, neither the overall slopes nor those of
the groups of patients defined by the underlying renal tively, 20.001 and 20.002 dL/mg/year, which means that
the loss of renal function in 25% of the patients was lessdisease were normally distributed. In the chronic glomer-
ulonephritis (CGN) groups, kurtosis (the statistic de- than 0.1% and 0.2%, and/or that some even had a posi-
tive slope (i.e., a gain in renal function over time). Thescribing the distribution pattern) was always higher and
the distribution was skewed to the left, thus suggesting percentages of patients with each underlying renal dis-
ease who had a positive slope during follow-up are showntheir heterogeneous nature. Slope variability was greater
in the CGN groups than in those with polycystic kidney in Table 2. In the groups of patients with hypertensive
nephroangiosclerosis (HNS) and chronic interstitial ne-disease (PKD), as can also be seen in Fig. 3 in which
the slopes are shown by renal diagnosis using the box- phritis (CIN) of both studies these percentages were
strikingly high (39% and 30% in the HNS and CINplot technique: the height of the box (which represents
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Fig. 2. Frequency distribution of the slopes of the reciprocal of SCr versus time in the AIPRI study [11] overall and according to renal disease.
groups of the NIC study; 31% and 29% in the HNS and Multivariate analysis
CIN groups of the AIPRI study); on the contrary they At univariate analysis, a number of covariates related
were much lower in the PKD groups (3% and 12% in to the slope of the reciprocal of SCr over time in both
the NIC and AIPRI studies, respectively). Conversely, studies (see Appendix 1).
the loss of renal function in another 25% of patients was, In the NIC study, age and the duration of follow-up
respectively, 6.3% and 8.0%, which means that despite were positively related to the slope (P , 0.0062 and
relatively low progression rate observed in the overall P , 0.0001, respectively), whereas high systolic blood
populations, a considerable number of the patients in pressure (P , 0.0435), a high degree of proteinuria (in
both studies experienced a clinically relevant annual loss
the log scale) (P , 0.0022) and PKD (in comparisonof renal function per year, with the fastest progression
with non PKD) (P , 0.0015) were associated with abeing observed in the lowest 5th percentile distribution
faster rate of progression. The contributory role of PKDof the AIPRI study (33.4%). When considering the rate
was greatest in the patients with mild CRF at baselineof progression by underlying renal disease (Table 2), we
(stratum A), with a more than 5% absolute differencefound that the patients with PKD, DN or (to a lesser
in the annual loss of renal function; it was less in theextent) CGN showed a specific and worse pattern than
intermediate stratum and complete absent in stratum C,the population as a whole, with the PKD patients having
in which baseline renal function was greatly compro-the worst distribution (median and 25th percentile of
mised (SCr . 5 mg/dL) (Fig. 4). Overall, this model ex-20.059 and 20.081 versus 20.027 and 20.063 in the NIC
plained 18% of the slope variability.study; 20.062 and 20.094 versus 20.029 and 20.080 dL/
In the AIPRI study, the slope of the reciprocal of SCrmg/year in the AIPRI study). In the AIPRI study, DN
versus time significantly correlated with baseline renalpatients also had a much worse distribution than the
function (a better slope for the patients with mild CRF;population as a whole (median and 25th percentile of
20.064 and 20.167 versus 20.029 and 20.080). P , 0.0005), mean follow-up proteinuria (in the log-
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Fig. 4. Representation of the contributory role of PKD at multivariate
analysis according to baseline renal function in the NIC study [10]. The
effect of the diagnosis of PKD was more relevant in patients with mild
CRF at baseline (Stratum A), lower in the intermediate stratum and absent
in the patients with heavy compromised renal function (Stratum C).
The results confirm that the underlying disease is asso-
ciated with the rate of CRF progression. In both studies,
the groups of patients with PKD and CGN experienced
a faster mean rate of CRF progression in comparison
with the other groups, although the small group of
NIDDM patients with DN in the AIPRI study also had a
fast CRF progression rate. Multivariate analysis showed
Fig. 3. Slopes of the reciprocal of SCr versus time by renal diagnosis that PKD was an independent predictor of the rate of
represented with the technique of the box-plots in the NIC [10] and
CRF progression only in the NIC study; other analysesAIPRI [11] studies. The zero reference line indicates no progression of
the renal disease; the height of the box represents the interquartile range. of cumulative renal survival in the same samples have
shown that PKD patients also have the highest probabil-
ity of reaching the end-points of a doubling in baseline
scale) (P , 0.0001), and the standard error of the slope SCr or the need for dialysis [11–13].
(P , 0.0001). These two last covariates were negatively The Modification of Diet in Renal Disease (MDRD)
related to the slope, with the higher values being associ- study [8] likewise found that PKD was the most progres-
ated with a more negative slope. There was also a signifi- sive chronic renal disease: in the PKD patients with mod-
erate CRF, the mean rate of CRF progression (estimatedcant interaction affecting slope prediction between mean
as the slope of GFR measured using the renal clearanceproteinuria and mean diastolic blood pressure during
of 125I-iothalamate) was 3.56 mL/min/year faster than infollow-up (P , 0.0001). A diagnosis of PKD did not
the patients with CGN or other nephropathies, althoughindependently contribute to the rate of CRF progression.
it was only 1.59 mL/min/year faster in the PKD patientsThis model explained 15% of the slope variability.
with more advanced CRF. This is in line with our obser-
vation that the predictivity of a PKD diagnosis as an
DISCUSSION independent marker of CRF progression decreases with
Assessing the rate of CRF progression is useful not the greater severity of baseline CRF (Fig. 4). The rate
only for prognostic purposes, but also for establishing the of progression of PKD observed in the MDRD study
effect of therapy on the natural history of renal disease; it [8] was similar to that observed by Jungers et al [6], who
is therefore crucial to acquire a greater understanding of found a lower rate of progression in PKD than in CGN
the natural history of CRF, the underlying nephropathies patients probably because of a selection bias towards
and the factors influencing their progression. This is why the more progressive forms of renal disease occurring
we wanted to analyze the rate of CRF progression in a in this retrospective study; other smaller and/or retro-
very large number of patients followed prospectively with spective studies have reported a lower rate of progres-
serial determinations of renal function over time, with sion in CIN and PKD patients than in those with CGN
the aim of better clarifying the contributory role of the or HNS [3, 4].
The greater contributory role of PKD in CRF progres-underlying renal disease in the natural history of CRF.
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Table 2. Percentile distribution of the slope of the reciprocal of SCr versus time in the NIC and AIPRI studies by renal diagnosis
CGN HNS CIN PKD DN Other Total
NIC Study
Positive slope
N 22/117 (19%) 25/64 (39%) 43/144 (30%) 2/69 (3%) — 1/20 (5%) 93/414 (23%)
Slope, dL/mg/year
95 percentile 0.052 0.047 0.068 20.006 — 0.167 0.048
75 percentile 20.003 0.009 0.009 20.042 — 20.010 20.001
Median 20.026 20.010 20.015 20.059 — 20.033 20.027
25 percentile 20.070 20.042 20.044 20.081 — 20.048 20.063
5 percentile 20.199 20.134 20.098 20.144 — 20.274 20.144
AIPRI Study
Positive slope
N 36/170 (21%) 31/99 (31%) 26/90 (29%) 7/57 (12%) 1/19 (5%) 10/37 (27%) 111/472 (24%)
Slope, dL/mg/year
95 percentile 0.087 0.107 0.096 0.073 — 0.041 0.076
75 percentile 20.003 0.009 0.007 20.025 20.023 0.002 20.002
Median 20.039 20.016 20.019 20.062 20.064 20.014 20.029
25 percentile 20.091 20.052 20.054 20.094 20.167 20.046 20.080
5 percentile 20.371 20.523 20.505 20.243 21.317 20.235 20.334
sion may be partially explained by the fact that the function (23% in the NIC and 24% in the AIPRI study).
growth rate and size of the cysts are probably the main Interestingly, these percentage varied considerably ac-
factors affecting progression in PKD patients with re- cording to the underlying renal disease, with the CIN
duced GFR; in patients with other nephropathies, CRF and HNS groups displaying the highest proportion of
progression may be due to more specific factors not nec- patients with a positive slope and the PKD group having
essarily related to the underlying disease, thus reducing the lowest percentage. This is in line with the results of
the predictive value of the disease itself. the MDRD study [8] showing that renal function was
Another important finding of this study is the extreme stable or improved during follow-up in 107/553 patients
variability in the rate of CRF progression. The greatest with moderate CRF (19%), and 27/219 with severe CFR
variability was observed in the CGN groups and may be (11%). The observation that CRF progression can spon-
explained by the fact that our “CGN” patients came taneously stabilize even for long periods is of particular
from at least two subpopulations with a different slope importance because it could question the general belief
and prognosis (see the distribution of CGN slopes in that, after a certain degree of renal damage has been
Fig. 1 and 2). Similar findings were obtained by the reached (the so-called “point of no return” [14]), and
MDRD study [8] and that of Jungers et al [6], both regardless of the cause, all CRF patients continue to lose
of which found a considerably greater between-patient renal function because renal failure itself may lead to
variability in the progression rate of CGN patients, maladaptive kidney alterations that give rise to a further
whereas distribution was more homogeneous in those loss of renal function. Given the highly variable natural
with PKD, CIN or vascular disease. history of renal disease, it also indicates that extreme
One limitation of our study may be the accuracy of caution is needed when evaluating the role of risk factors
diagnosis. Although the underlying renal disease was
and treatment effect [15].
carefully assessed by means of a number of clinical, labo-
The results of the multivariate analyses of the NIC andratory and radiological examinations in both studies, the
AIPRI studies were different: age, the length of follow-updiagnosis of HNS was often presumptive, and it is possi-
and PKD were found to be related to the slope of theble that some cases of renovascular disease or CGN may
reciprocal of SCr versus time in the NIC but not the AIPRIhave passed unnoticed. Furthermore, the diagnosis of
study, and baseline renal function and the standard errorCIN was certainly overexpressed during the 1980s because
of the slope significantly correlated with the rate of CRFultrasonography was not widely available and renal biopsy
progression only in the AIPRI study. Proteinuria (base-was less used in clinical practice; this seems to be partially
line in the NIC and during follow-up in the AIPRI study)true in the case of the present analysis (there were more
was negatively related to the rate of CRF progressionCIN patients in the NIC than in the AIPRI study).
in both studies, but a significant interaction between pro-Despite the relatively low progression rate observed
teinuria and diastolic blood pressure during follow-upin the NIC and AIPRI populations, we found that a
was only found in the AIPRI study. Systolic blood pres-good number of patients experienced a clinically relevant
sure was related to a faster progression rate in the NICannual loss of renal function, whereas many maintained
but not in the AIPRI study, probably because of the morea relatively stable renal function or even had a positive
slope partially regardless of treatment and baseline renal intensive approach to blood pressure control adopted over
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4. Stenvinkel P, Alverstrand A, Bergstro¨m J: Factors influencingthe last few years (the AIPRI patients were enrolled
progression in patients with chronic renal failure. J Intern Medsome years later than those in the NIC study). 226:183–188, 1989
It is important to underline that the models of multi- 5. Wight JP, Salzano S, Brown CB, El Nahas AM: Natural history
of chronic renal failure: a reappraisal. Nephrol Dial Transplantvariate analyses of the NIC and AIPRI studies predict,
7:379–383, 1992respectively, only 18% and 15% of the variation in the 6. Jungers P, Hannnedouche T, Itakura Y, Albouze G, Descamps-
CRF progression rate, thus indicating that other un- Latscha B, Man NK: Progression rate to end-stage renal failure
in non-diabetic kidney diseases: a multivariate analysis of determi-known factors have a considerable effect on progression.
nant factors. Nephrol Dial Transplant 10:1353–1360, 1995The extreme variability observed in the rate of CRF 7. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour
progression in individual patients further stresses the B, Jungers P: Factors affecting progression in advanced chronic
renal failure. Clin Nephrol 39:312–320, 1993complexity of the phenomena by suggesting the involve-
8. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T,ment of disease-specific pathogenetic factors rather than
Kusek JW, Rogers NL, Teshan PE and the Modification of
a single common mechanism of progression. In this light, Diet in Renal Disease Study Group: Predictors of the progression
future studies of the contributory role of genetic factors, of renal disease in the Modification of Diet in Renal Disease Study.
Kidney Int 51:1908–1919, 1997as well as that of altered cytokine or growth factor pro-
9. Jovanovic DB, Djukanovic LD: Analysis of factors influencingduction, should lead to a greater understanding of the chronic renal failure progression. Renal Failure 21:177–187, 1999
other mechanisms involved in CRF. 10. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B,
Giangrande A: Prospective, randomised, multicentre trial of effectIn conclusion, this study of two large samples of CRF
of protein restriction on progression of chronic renal insufficiency.patients confirms that the underlying renal disease cer-
Northern Italian Cooperative Study Group. Lancet 337:1299–1304,
tainly plays a role in the natural history of chronic renal 1991
failure. However, the highly variable rates of CRF pro- 11. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Mo-
tolese M, Ponticelli C, Ritz E, Zucchelli P and the Angioten-gression between the different diagnostic groups, as well
sin-Converting-Enzyme Inhibition in Progressive Renal Insuf-as between the individuals with the same diagnosis, under- ficiency Study Group: Effect of the Angiotensin-Converting-
line the fact that extreme caution is needed when assessing Enzyme inhibitor benazepril on the progression of chronic renal
insufficiency. N Engl J Med 334:939–945, 1996risk factors and predicting individual patient outcomes.
12. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B,Although this study offers a number of epidemiological
Giangrande A, Marcelli D, Francucci BM and the Northern
insights into the behavior of chronic renal diseases, the Italian Cooperative Study Group: Factors affecting chronic renal
need to put patients with different diseases in a single failure progression: results from a multi-centre trial. Miner Electro-
lyte Metab 18:295–302, 1992diagnosis group (CGN, but also CIN and PKD) and the
13. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G,unreliability of nonhistological diagnoses (often made in Buccianti G, Redaelli B, Giangrande A and the Northern
the case of many patients with HNS or CIN in everyday Italian Cooperative Study Group: Proteinuria and blood pres-
sure as causal components of progression to end-stage renal failure.clinical practice) undoubtedly affected the results. Fur-
Nephrol Dial Transplant 11:461–467, 1996ther studies of large but more homogenous samples are
14. Maschio G, Oldrizzi L, Rugiu C: Is there a ‘point of no return’
therefore needed to improve our understanding of the in progressive renal disease? J Am Soc Nephrol 2:832–840, 1991
natural history of each nephropathy and lay the basis for 15. Locatelli F, Del Vecchio L, Andrulli S: REIN follow-up trial
(letter). Lancet 352:2020–2021, 1998the development of more specific therapeutic approaches.
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